Natalizumab

ATC Code L04AG03

Natalizumab

Definition

A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Natalizumab binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins expressed on the surface of all leukocytes except neutrophils, inhibiting the alpha4-mediated adhesion of leukocytes to counter-receptor(s) such as vascular cell adhesion molecule-1 (VCAM-1); natalizumab-mediated disruption of VCAM-1 binding by these integrins may prevent the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue. Integrins are cellular adhesion molecules (CAMs) that are upregulated in various types of cancer and some autoimmune diseases; alpha4beta1 integrin (VLA4) has been implicated in the survival of myeloma cells, possibly by mediating their adhesion to stromal cells.

Also known as AN100226, Antegren, Anti-alph4 Integrin Monoclonal Antibody AN100226, Anti-VLA4, NATALIZUMAB, Tysabri — per NCIT

Also identified as

Indications

Disease Relation Source
Crohn's disease may treat MEDRT · Public domain (U.S. Government work)
Multiple sclerosis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Alimentary part of gastrointestinal system may treat a disease of this organ DERIVED · CC BY 4.0
Central nervous system may treat a disease of this organ DERIVED · CC BY 4.0
Intestine may treat a disease of this organ DERIVED · CC BY 4.0
Nervous system may treat a disease of this organ DERIVED · CC BY 4.0

4 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.